NEW HAVEN, Conn., Nov. 4, 2021 /PRNewswire/ -- Biohaven
Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a
commercial-stage biopharmaceutical company with a portfolio of
innovative, late-stage product candidates targeting neurological
and neuropsychiatric diseases, will hold its upcoming third quarter
2021 earnings call and webcast, reporting financial results for the
quarter ended September 30, 2021 and
provide a review of recent accomplishments and anticipated upcoming
milestones, on Tuesday November 9, 2021 at 8:00 a.m. ET.
To access the call, please dial 877-407-9120 (domestic) or
412-902-1009 (international). The conference call webcast and
accompanying slide presentation can be accessed through the
"Investors" section of Biohaven's website at
www.biohavenpharma.com. To ensure a timely connection, it is
recommended that participants register at least 15 minutes prior to
the scheduled webcast. A replay of the call will be made available
for two weeks following the conference call. To hear a replay of
the call, dial 877-660-6853 (domestic) or 201-612-7415
(international) with conference ID 13723890. An archived webcast
will be available on Biohaven's website.
About Biohaven
Biohaven is a commercial-stage
biopharmaceutical company with a portfolio of innovative,
best-in-class therapies to improve the lives of patients with
debilitating neurological and neuropsychiatric diseases, including
rare disorders. Biohaven's neuroinnovation™ portfolio includes
FDA-approved NURTEC ODT (rimegepant) for the acute treatment of
migraine and a broad pipeline of late-stage product candidates
across three distinct mechanistic platforms: CGRP receptor
antagonism for the acute and preventive treatment of migraine;
glutamate modulation for obsessive-compulsive disorder, Alzheimer's
disease, and spinocerebellar ataxia; and MPO inhibition for
multiple system atrophy and amyotrophic lateral sclerosis. More
information about Biohaven is available at
www.biohavenpharma.com.
NURTEC is a trademark of Biohaven Pharmaceutical Ireland
DAC.
Neuroinnovation is a trademark of Biohaven Pharmaceutical
Holding Company Ltd.
Biohaven Contact:
Dr. Vlad Coric
Chief Executive Officer
Vlad.Coric@biohavenpharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/biohaven-to-report-third-quarter-2021-financial-results-and-recent-business-developments-on-november-9-2021-301416388.html
SOURCE Biohaven Pharmaceutical Holding Company Ltd.